LYA-Neuro 3 Drug Detail
Label-linked therapy, administration, access, and operational details for provider teams.
NDC: 00000-303-21
Route: Infusion
HCPCS: Q9999 (temporary pass-through)
REMS: Yes
Clinical Profile
Core facts providers need during therapy onboarding and maintenance.
Provider Tools
Common resources used by office and infusion teams.
Monitoring and Administration Workflow
Operational checkpoints used across provider, nursing, and reimbursement staff.
Contraindications
- Prior class-related severe adverse reaction
- Uncontrolled hepatic impairment pending specialist review
Administration Notes
- Induction phase followed by maintenance every 8 weeks
- Infusion rate titration per protocol for high-risk patients
- Post-infusion neurologic observation in cycle 1
Monitoring Matrix
Baseline
Required: Neurologic functional score + MRI baseline
Owner: Neurology provider
Maintenance
Required: Lab panel before each infusion
Owner: Infusion center
Annual
Required: MRI reassessment and outcomes review
Owner: Provider
Distribution and Access
Supply, coding, and payer preparation details.
Site type
Certified infusion centers only
REMS onboarding
Required before first dispense
Replacement process
24-hour product quality hotline
Payer Readiness
Evidence package components frequently requested for initial authorization.
Relapse history threshold
Recommended evidence: Neurology chart summary
MRI activity confirmation
Recommended evidence: Radiology report
Prior regimen failure/intolerance
Recommended evidence: Treatment timeline
Interaction Watchouts
- Coordinate corticosteroid bursts around infusion scheduling
- Review antiepileptic adjustments for sedation overlap
Capture Local Notes
Add site-specific details that are not in national references.
Add Drug Detail Note
Capture local administration, coverage, or logistics notes.
Add Access Escalation
Log payer obstacle details and escalation owner for this therapy.